{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825893668440320.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1365-2141.2010.08524.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2141.2010.08524.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2141.2010.08524.x"}}],"dc:title":[{"@value":"The frequency and management of asparaginase‐related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana‐Farber Cancer Institute consortium protocols"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Summary</jats:title><jats:p>The optimal management of asparaginase‐associated thrombotic complications is not well‐defined. We report the features, management and outcome of paediatric (ages 0–18 years) and adult (18–50 years) patients with acute lymphoblastic leukaemia (ALL) with asparaginase‐related venous thromboembolic events (VTE) treated at Dana‐Farber Cancer Institute on clinical trials for newly diagnosed ALL between 1991–2008. Of 548 patients, 43 (8%) had VTE, including 27/501 (5%) paediatric and 16/47 (34%) adult patients. Sinus venous thrombosis occurred in 1·6% of patients. Age was the only significant predictor of VTE, with those aged >30 years at very high risk (VTE rate 42%). 74% of patients received low molecular weight heparin after VTE. Complications of anticoagulation included epistaxis (9%), bruising (2%) and, in two adult patients, major bleeding. Thirty patients (70%) ultimately received at least 85% of the intended doses of asparaginase. 33% of patients experienced recurrent VTE (paediatric 17% vs. adults 47%, <jats:italic>P</jats:italic> = 0·07). The 48‐month event‐free survival for patients with VTE was 85 ± 6% compared with 88 ± 2% for those without VTE (<jats:italic>P</jats:italic> = 0·36). This study confirms that, after VTE, asparaginase can be restarted with closely monitored anticoagulation after imaging demonstrates clot stabilization or improvement. With this management strategy, a history of VTE does not appear to adversely impact prognosis.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825893668440192","@type":"Researcher","foaf:name":[{"@value":"Rachael F. Grace"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893668440324","@type":"Researcher","foaf:name":[{"@value":"Suzanne E. Dahlberg"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893668440193","@type":"Researcher","foaf:name":[{"@value":"Donna Neuberg"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893668440320","@type":"Researcher","foaf:name":[{"@value":"Stephen E. Sallan"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893668440321","@type":"Researcher","foaf:name":[{"@value":"Jean M. Connors"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893668440325","@type":"Researcher","foaf:name":[{"@value":"Ellis J. Neufeld"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893668440322","@type":"Researcher","foaf:name":[{"@value":"Daniel J. DeAngelo"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893668440323","@type":"Researcher","foaf:name":[{"@value":"Lewis B. Silverman"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00071048"},{"@type":"EISSN","@value":"13652141"}],"prism:publicationName":[{"@value":"British Journal of Haematology"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2011-01-07","prism:volume":"152","prism:number":"4","prism:startingPage":"452","prism:endingPage":"459"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2141.2010.08524.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2141.2010.08524.x"}],"createdAt":"2011-01-07","modifiedAt":"2023-10-15","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360013168769272832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Anticoagulation treatment and prophylactic edoxaban for cerebral sinus venous thrombosis in an adolescent with acute lymphoblastic leukemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360849941067566848","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Supportive care for hemostatic complications associated with pediatric leukemia: a national survey in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1361131414732863104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L‐asparaginase induction therapy in pediatric acute lymphoblastic leukemia"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1365-2141.2010.08524.x"},{"@type":"CROSSREF","@value":"10.1177/2050313x211013225_references_DOI_RRTLRhsZTgREyaXPyn4pVQwkVMK"},{"@type":"CROSSREF","@value":"10.1007/s12185-019-02740-9_references_DOI_RRTLRhsZTgREyaXPyn4pVQwkVMK"},{"@type":"CROSSREF","@value":"10.1002/pbc.28016_references_DOI_RRTLRhsZTgREyaXPyn4pVQwkVMK"}]}